Skip to main content

Year: 2023

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation – – 21.6% Reduction in Vascular Inflammatory Marker High Sensitivity C-reactive Protein (hsCRP) in Patients Taking Bempedoic Acid – – Results Simultaneously Published in Circulation – ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published in Circulation which can be accessed here. “The analysis presented at AHA and published in Circulation highlights...

Continue reading

Uponor Corporation – Managers’ transactions: Hans Sohlström

Uponor Corporation, Managers’ transactions, 13 November 2023 at 16:30 EET Uponor Corporation – Managers’ transactions: Hans Sohlström Transaction notification under Article 19 of EU Market Abuse Regulation. Person subject to the notification requirementName: Sohlström, HansPosition: Member of the Board/Deputy memberIssuer: Uponor CorporationLEI: 743700KA2GMSYJM3CM12 Notification type: INITIAL NOTIFICATIONReference number: 743700KA2GMSYJM3CM12_20231113135812_102 ____________________________________________ Transaction date: 2023-11-13Venue: XHELInstrument type: SHAREISIN: FI0009002158Nature of the transaction: DISPOSAL Transaction details(1): Volume: 6,666 Unit price: 28.50 EUR Aggregated transactions(1): Volume: 6,666 Volume weighted average price: 28.50 EUR Further information:Franciska JanzonSenior Vice President, Corporate Communications...

Continue reading

Wearable Devices Announces Closing of $2.0 Million Underwritten Public Offering

YOKNEAM ILLIT, ISRAEL, Nov. 13, 2023 (GLOBE NEWSWIRE) —  Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in AI-powered touchless sensing wearables, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company of $2.0 million, before deducting underwriting discounts and other expenses paid by the Company. The base offering consisted of 4,444,444 ordinary shares priced to the public at $0.45 per share. The Company intends to use the proceeds from this offering for working capital and general corporate purposes. In addition, the Company granted Aegis Capital Corp. a 45-day option to purchase ordinary shares of up to 15% of the number of ordinary shares sold in the offering solely to cover over-allotments,...

Continue reading

Uponor Corporation – Managers’ transactions: Susanne Skippari

Uponor Corporation, Managers’ transactions, 13 November 2023 at 16:25 EET Uponor Corporation – Managers’ transactions: Susanne Skippari Transaction notification under Article 19 of EU Market Abuse Regulation. Person subject to the notification requirementName: Skippari, SusannePosition: Member of the Board/Deputy memberIssuer: Uponor CorporationLEI: 743700KA2GMSYJM3CM12 Notification type: INITIAL NOTIFICATIONReference number: 743700KA2GMSYJM3CM12_20231113135812_98 ____________________________________________ Transaction date: 2023-11-13Venue: XHELInstrument type: SHAREISIN: FI0009002158Nature of the transaction: DISPOSAL Transaction details(1): Volume: 2,026 Unit price: 28.50 EUR Aggregated transactions(1): Volume: 2,026 Volume weighted average price: 28.50 EUR Further information:Franciska JanzonSenior Vice President, Corporate Communications...

Continue reading

Kayne Anderson Energy Infrastructure Fund Announces Completion of Merger with Kayne Anderson NextGen Energy & Infrastructure

HOUSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) — Kayne Anderson Energy Infrastructure Fund, Inc. (NYSE: KYN) announced today the completion of the merger of Kayne Anderson NextGen Energy & Infrastructure, Inc. (NYSE: KMF) with KYN (the “Merger”). KMF was merged with and into a wholly owned subsidiary of KYN, and KMF stockholders received either (i) newly issued common stock of KYN (“Stock Consideration”) or (ii) cash (“Cash Consideration”), subject to the adjustment and proration procedures as set forth in the merger agreement. The exchange rate for Stock Consideration was based on each fund’s relative net asset value (“NAV”) per share as of November 10, 2023, and the per share Cash Consideration was based on 95% of the NAV per share of KMF’s common stock as of the same date, as listed below:Surviving Fund NAV per shareKayne...

Continue reading

MEGA MATRIX CORP. Reports Third Quarter 2023 Financial Results

Mega Matrix New York Stock ExchangeListed Powerhouse is driving the Ethereum movement.Discover the gateway of Ethereum’s potential.Your journey to profits starts now. Embrace Ethereum’s rise.Elevate your investments.Mega Matrix Unleash the power of Ethereum.PALO ALTO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Mega Matrix Corp. (“MPU” or the “Company”) (NYSE American: MPU), today announced financial results for its third quarter ended September 30, 2023. Financial HighlightsThe Company had cash and cash equivalents of $2.0 million, and total liquidity (defined as cash equivalents and restricted cash, stable coins and digital assets) of approximately $7.0 million, as of September 30, 2023. Total assets were $9.0 million as of September 30, 2023. Equity attributable to MPU’s...

Continue reading

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Achieved significant enrollment milestones in ongoing Phase 2 clinical trials Four ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS Ended third quarter 2023 with $94.0 million of cash and cash equivalentsSEATTLE, Nov. 13, 2023 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended September 30, 2023, and provides an update on recent company developments. Key developments from Q3 2023 and year to date include:80% Enrollment in Ongoing Phase 2 Karisma-Endoxifen Clinical Trial – the study is investigating (Z)-endoxifen in premenopausal women with measurable breast...

Continue reading

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said: “Recently, two significant events occurred that we believe demonstrate confidence in our ongoing mission to bring to market a therapy for NASH cirrhosis patients where none currently exists. First, in late September 2023, our Board Chairman, Richard E. Uihlein, exercised 2,236,204 common stock purchase...

Continue reading

Hamilton Thorne Reports Revenue for the Quarter and Nine Months Ended September 30, 2023

Revenue up 16% to $15.7 million and Adjusted EBITDA up 3% to $2.2 million for the quarter BEVERLY, Mass. and TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) — Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the quarter and nine months ended September 30, 2023. Financial HighlightsSales increased 16% year over year to $15.7 million for the quarter; sales for the nine-month period increased 17% to $41.8 million; sales increased 12% for the quarter and 16% for the nine-month period on a constant currency basis Gross profit increased 18% to $7.7 million for the quarter; increased 21% to $24.7 million for the nine-month period Adjusted EBITDA increased...

Continue reading

OSS Unveils New Gen 5 AI Transportable Compute Server

OSS Gen 5 Server Doubles Performance — Powering the Most Demanding Intelligent Edge ApplicationsGen 5 Short-Depth Server (SDS)OSS new Gen 5 AI Transportable compute server doubles the performance over previous generation for powering the most demanding intelligent edge applications.ESCONDIDO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (Nasdaq: OSS), a leader in rugged High Performance Compute (HPC) for Artificial Intelligence (AI), Machine Learning and sensor processing at the edge, will unveil today its latest AI Transportable, a Gen 5 short-depth server (SDS), at SC23, the international conference for high performance computing being held in Denver, Colorado on November 12-17, 2023. Gen 5 Short-Depth Server (SDS)OSS new Gen 5 AI Transportable compute server doubles the performance over previous...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.